Next 10 |
home / stock / asmb / asmb articles
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses an...
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at ...
Alexander Schornstein, 10% Owner at Assembly Biosciences (NASDAQ:ASMB), reported a large insider buy on November 22, according to a new SEC filing....
--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFN? pathway through a liver-focused approach to improve...
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- ...
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09%...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones falling gaining around 100 points on Tuesday. The Dow traded up 0....
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday. Following the market opening Tuesday, the Dow tra...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-04-07 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with rec...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...